---
title: "Ralliant climbs 6%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304133229.md"
description: "Ralliant rose 5.56% to US$70.00. Up 37.48% YTD."
datetime: "2026-11-03T14:43:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304133229.md)
  - [en](https://longbridge.com/en/news/304133229.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304133229.md)
generator: "portal-rs"
---

# Ralliant climbs 6%

Ralliant (RAL.US) climbed nearly **6%** during regular trading to **$70.00**.

The stock is up 37.48% year to date and sits 88.37% above its 52-week low of US$37.16. Volume was 0.36 times its average.

The Nasdaq Composite is down 4.23% over the past five sessions and up 9.11% year to date.

The electronic equipment and instruments industry index rose 2.8% over the same period.

Seaport Global upgraded the stock to Buy with a price target of $88.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [RAL.US](https://longbridge.com/en/quote/RAL.US.md)

## Related News & Research

- [Ralliant President and CEO Tamara S. Newcombe Reports Disposal of $869,040.48 in Common Shares](https://longbridge.com/en/news/306045453.md)
- [Is Ralliant (RAL) Fully Valued Following Its Higher Full Year Revenue Outlook?](https://longbridge.com/en/news/305401979.md)
- [Space Exploration Technologies (SPCX) Gets A New Hiring Twist As Musk Eyes Top AI Talent](https://longbridge.com/en/news/306383945.md)
- [Salesforce (CRM) Chosen To Lead U.S. Backed Super Intelligence Export Group](https://longbridge.com/en/news/306383121.md)
- [CAPR: FDA issued a CRL for Deramiocel, citing insufficient evidence of effectiveness](https://longbridge.com/en/news/306366333.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**